Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 8/20 | 0.47 |
| ▸ | ACP1 | P24666 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945354 | 0.84 | FYN (0.51) | FYNNPC1RAB9AF2RL3PIK3CG | |
| SCHEMBL1944720 | 0.84 | FYN (0.48) | FYNACP1NPC1RAB9AF2RL3 | |
| SCHEMBL1944055 | 0.84 | GBA1 (0.48) | FYNNPC1RAB9A | |
| SCHEMBL1651704 | 0.84 | FYN (0.49) | FYNACP1NPC1RAB9AF2RL3 | |
| SCHEMBL1944774 | 0.83 | ACP1 (0.40) | ACP1NPC1RAB9AF2RL3PIK3CA | |
| SCHEMBL1944767 | 0.83 | FYN (0.44) | FYNACP1NPC1RAB9AF2RL3 | |
| SCHEMBL1944739 | 0.83 | FYN (0.68) | FYNNPC1RAB9A | |
| SCHEMBL1944192 | 0.83 | TP53 (0.49) | ACP1NPC1RAB9AF2RL3 | |
| SCHEMBL1945197 | 0.81 | FYN (0.66) | FYNACP1NPC1RAB9AF2RL3 | |
| SCHEMBL1944717 | 0.81 | HSP90AA1 (0.44) | FYNNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | TGFBR1, TGFBR2, IGF1R | FYN 1977/4885ACP1 2731/4885NPC1 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.